GCV Symposium 2017
Skip Content

27 July 2012

Cell Medica raises $26.5m

Invesco Perpetual, the fund manager, and Imperial Innovations, the London Stock Exchange-listed spin-off from Imperial College London, are joined by The Cancer Prevention and Research Institute of Texas and the Wellcome Trust supporting Cell Medica's growth.

Author: Toby Lewis, editor, Global Corporate Venturing

Invesco Perpetual, the fund manager, and Imperial Innovations, the London Stock Exchange-listed spin-off from Imperial College London, have helped UK-basedcell therapy developer Cell Medica raise £17m ($26.5m).

The Cancer Prevention and Research Institute of Texas has also offered $15.3m to back Cell Medica's cancer immunotherapy technology licensed from Baylor College of Medicine.

Thomas Hecht, the former vice president of marketing in Europe for Amgen is becoming chairman and UK-based foundation the Wellcome Trust is converting its investment in the company into equity.

Copyright Mawsonia Limited 2010. Please don´t cut articles from www.globaluniversityventuring.com or the PDF and redistribute by email or post to the web without written permission.

  • Linkedin
  • Mail
  • Rssfeed
Trial Subscribe now

Latest Magazine

GCV Symposium 2017

Editor’s picks

Most popular

Events

23 April 2017

UniVenture Visions 2017 Symposium – Hong Kong

The Coller Institute of Venture and the AUTM Asia 2017 Conference have announced UniVenture Visions, an exclusive symposium that shall trigger the thinking and discussion necessary to evolve research universities…

23 May 2017

GCV Symposium 2017 - London

Join 400+ business leaders from the corporate venturing and wider high growth business ecosystem for the two-day 2017 GCV Symposium.